An interventional study of Verapamil hydrochloride and Conventional treatment in Chronic Obstructive Pulmonary Disease and Acute Exacerbation of Chronic Obstructive Pulmonary Disease, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 41 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment
This clinical trial evaluated whether adding nebulized verapamil to conventional treatment could improve oxygenation and clinical status in patients hospitalized with an acute exacerbation of chronic obstructive pulmonary disease (COPD).
A total of 60 participants were randomly assigned to two groups. One group received nebulized verapamil in addition to conventional treatment, while the other group received conventional treatment alone. Nebulized verapamil was given at a dose of 10 mg twice daily for three consecutive days. The study assessed changes in oxygenation, respiratory function, symptoms, functional status, and cardiovascular safety during the treatment period.
4,252 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 707 are open to participants now.
This study's enrollment of 60 is below the median of 70 across 3,008 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Browse Pulmonary Disease, Chronic Obstructive studies →Ain Shams University is the lead sponsor of 1,930 studies on the registry; 433 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received verapamil hydrochloride 10 mg by nebulization twice daily for 3 consecutive days, in addition to conventional treatment. Verapamil was prepared from two 5-mg ampoules at a concentration of 2.5 mg/mL, giving a total volume of 4 mL per dose, and was administered using a compressed-air jet nebulizer. Conventional treatment included antibiotics and bronchodilators.
Drug: Verapamil hydrochloride
Participants received conventional treatment alone for 3 consecutive days, including antibiotics and bronchodilators.
Other: Conventional treatment
Verapamil hydrochloride was administered by nebulization at a dose of 10 mg twice daily for 3 consecutive days, for a total of 6 scheduled doses. Each dose was prepared from two 5-mg ampoules at a concentration of 2.5 mg/mL, providing a total volume of 4 mL, and was administered using a compressed-air jet nebulizer.
Conventional treatment for acute exacerbation of COPD included antibiotics and bronchodilators and was administered during the 3-day study period.
Change in Peripheral Oxygen Saturation (SpO₂)
Peripheral oxygen saturation was measured by pulse oximetry. Change in SpO₂ during the 3-day treatment period was compared between the nebulized verapamil and control groups.
Time frame: Baseline on Day 1 through Day 3 after the second scheduled dose
Change in Arterial Oxygen Partial Pressure (PaO₂)
Arterial oxygen partial pressure (PaO₂), measured in mmHg by arterial blood gas analysis, was assessed during the 3-day treatment period.
Time frame: Baseline on Day 1 through Day 3 after the second scheduled dose
Change in Arterial Carbon Dioxide Partial Pressure (PaCO₂)
Arterial carbon dioxide partial pressure (PaCO₂), measured in mmHg by arterial blood gas analysis, was assessed during the 3-day treatment period.
Time frame: Baseline on Day 1 through Day 3 after the second scheduled dose
Change in Arterial Blood pH
Arterial blood pH was measured by arterial blood gas analysis during the 3-day treatment period.
Time frame: Baseline on Day 1 through Day 3 after the second scheduled dose
Change in Serum Bicarbonate (HCO₃-)
Bicarbonate concentration (HCO₃-), measured in mmol/L by arterial blood gas analysis, was assessed during the 3-day treatment period.
Time frame: Baseline on Day 1 through Day 3 after the second scheduled dose
Change in Forced Expiratory Volume in One Second (FEV₁)
FEV₁ was measured by spirometry in liters before treatment and after completion of the 3-day intervention.
Time frame: Baseline to Day 3
Change in Forced Vital Capacity (FVC)
FVC was measured by spirometry in liters before treatment and after completion of the 3-day intervention.
Time frame: Baseline to Day 3
Change in FEV₁/FVC Ratio
The ratio of forced expiratory volume in one second to forced vital capacity was measured by spirometry before and after treatment.
Time frame: Baseline to Day 3
Change in Maximum Mid-Expiratory Flow at 50% of FVC (MMEF50)
MMEF50 was measured by spirometry before treatment and after completion of the 3-day intervention.
Time frame: Baseline to Day 3
Change in Right Ventricular Systolic Pressure (RVSP)
RVSP, measured in mmHg by transthoracic echocardiography, was assessed before treatment and after completion of the 3-day intervention.
Time frame: Baseline to Day 3
Change in Modified Borg Dyspnea Score
Dyspnea severity was assessed using the modified Borg scale ranging from 0, indicating no dyspnea, to 10, indicating maximal dyspnea.
Time frame: Baseline to Day 3
Change in World Health Organization Functional Class
Functional limitation was assessed using World Health Organization functional class, ranging from Class I, indicating no limitation of physical activity, to Class IV, indicating symptoms at rest and severe functional limitation.
Time frame: Baseline to Day 3
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Verapamil
Pulmonary Disease, Chronic Obstructive →